Pulmonary Disease, Chronic Obstructive
Conditions
Keywords
COPD, asthma, smokers, healthy volunteers, bronchiectasis, cystic fibrosis
Brief summary
Evaluation of OPG level as disease markers has also been reported. It has been showed that patients with coronary artery disease had higher serum OPG levels than healthy volunteers. Moreover, serum OPG levels correlate with the number of stenotic coronary arteries
Detailed description
Osteoprotegerin (OPG) is a secreted glycoprotein containing 401 amino acids. It is a member of the tumour necrosis factor (TNF) receptor superfamily. It was firstly discovered as a protein regulating bone metabolism, inhibiting osteoclastogenesis, consequently, inhibiting bone resorption OPG is detected in lung using Northern blot analysis. It is likely that OPG would contribute to the pathogenesis of COPD and could be an effective disease marker of the disease
Interventions
PROCEDUREInduced sputum
Used Ultrasonic nebuliser
Sponsors
Imperial College London
Study design
Observational model
OTHER
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
35 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
* Healthy non-smokers * Age \<35 years (younger group) * Aged matched to COPD patients (older group) * Normal spirometry * Subjects are able to give informed consent * Healthy smokers * Age \<35 years (younger group) * Aged matched to COPD patients (older group) * Normal spirometry * Subjects are able to give informed consent Stable COPD patients: Stage I-IV according to the GOLD guidelines (3), (9) * Current and/or ex-smokers with no less than 10 pack-year smoking history * The subjects are able to give informed consent COPD patients with acute exacerbation: Stage I-IV according to the GOLD guidelines (3), (9) * Exacerbation of COPD defined as an event in the natural course of the disease characterised by a change in the patient's baseline dyspnoea, cough and/or sputum beyond day to day variability sufficient to warrant a change in management (9) * Current and/or ex-smokers with no less than 10 pack-year smoking history * The subjects are able to give informed consent Asthma patients * Patients diagnosed with asthma * The subjects are able to give informed consent Bronchiectasis patients * Patients with CT-confirmed bronchiectasis * The subjects are able to give informed consent Cystic fibrosis patients * Patients diagnosed with cystic fibrosis * The subjects are able to give informed consent
Exclusion criteria
* Healthy non-smokers and smokers * Upper respiratory infection within the last 4 weeks. * Subjects who have received research medication within the previous one month. * Subjects unable to give informed consent. * Any psychiatric condition rendering the patient unable to understand the nature, scope and possible consequences of the study Stable COPD patients * Patients who have had an exacerbation which required treatment with oral steroids during the last 2 months prior to the visit * Upper respiratory infection within the last 4 weeks * Subjects who have received research medication within the previous one month * Subjects unable to give informed consent * Any psychiatric condition rendering the patient unable to understand the nature, scope and possible consequences of the study COPD patients with acute exacerbation * Subjects who have received research medication within the previous one month * Subjects unable to give informed consent * Any psychiatric condition rendering the patient unable to understand the nature, scope and possible consequences of the study Asthma * Upper respiratory infection within the last 4 weeks * Subjects who have received research medication within the previous one month * Subjects unable to give informed consent. * Any psychiatric condition rendering the patient unable to understand the nature, scope and possible consequences of the study. * Bronchiectasis and cystic fibrosis * Subjects who have received research medication within the previous one month. * Subjects unable to give informed consent. * Any psychiatric condition rendering the patient unable to understand the nature, scope and possible consequences of the study.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Sputum OPG | 1 hour | Sputum OPG as assessed by ELISA at baseline |
Countries
United Kingdom
Outcome results
None listed